Indeed, THZ1, a covalent inhibitor of CDK7, was found to selectively target MYCN-amplified NB cells, leading to global repression of MYCN-dependent transcriptional amplification and reductions in expression of SE-associated oncogenic drivers including MYCN itself and suppression of NB tumor xenograft growth (87). The gene discussed is MYCN; the disease is neuroblastoma.